Hematopoietic stem cell gene therapy for the cure of blood diseases: primary immunodeficiencies

Cristina Cifaldi, Francesca Ferrua, Alessandro Aiuti, Caterina Cancrini

Research output: Contribution to journalReview article

Abstract

This report provides an overview of gene therapy use of stem cell for the treatment of primary immunodeficiencies (PIDs). Human stem cells are non-specialized cells, able to differentiate, starting from the embryo and for the whole duration of the life of each individual, into different cell types, through two types of cell division: symmetrical creating two stem cells and asymmetric differentiating to any cell lineage. These cells represented the ideal target for gene correction to guarantee production of engineered multi-lineage progeny. Their use in gene therapy led to the development of an effective treatment for PIDs, such as ADA deficiency, SCID-X1, WAS, CGD, and providing potential long-term clinical benefit for affected patients.

Original languageEnglish
Pages (from-to)755-764
Number of pages10
JournalRendiconti Lincei
Volume29
Issue number4
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

hematologic diseases
gene therapy
Hematologic Diseases
immunosuppression
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Genetic Therapy
Stem Cells
blood
stem cells
gene
stem
Cell Lineage
cells
Cell Division
embryo
Embryonic Structures
cell division
embryo (animal)
Therapeutics

Keywords

  • Adenosine deaminase deficiency
  • Chronic granulomatous disease
  • Gene therapy
  • Hematopoietic stem cells
  • Primary immunodeficiencies
  • RAGs defect
  • SCID-X1
  • Wiskott–Aldrich syndrome
  • XLP1 disease

ASJC Scopus subject areas

  • Environmental Science(all)
  • Agricultural and Biological Sciences(all)
  • Earth and Planetary Sciences(all)

Cite this

Hematopoietic stem cell gene therapy for the cure of blood diseases : primary immunodeficiencies. / Cifaldi, Cristina; Ferrua, Francesca; Aiuti, Alessandro; Cancrini, Caterina.

In: Rendiconti Lincei, Vol. 29, No. 4, 01.12.2018, p. 755-764.

Research output: Contribution to journalReview article

@article{061903704b3c4b4d810b703f4fb0c1b8,
title = "Hematopoietic stem cell gene therapy for the cure of blood diseases: primary immunodeficiencies",
abstract = "This report provides an overview of gene therapy use of stem cell for the treatment of primary immunodeficiencies (PIDs). Human stem cells are non-specialized cells, able to differentiate, starting from the embryo and for the whole duration of the life of each individual, into different cell types, through two types of cell division: symmetrical creating two stem cells and asymmetric differentiating to any cell lineage. These cells represented the ideal target for gene correction to guarantee production of engineered multi-lineage progeny. Their use in gene therapy led to the development of an effective treatment for PIDs, such as ADA deficiency, SCID-X1, WAS, CGD, and providing potential long-term clinical benefit for affected patients.",
keywords = "Adenosine deaminase deficiency, Chronic granulomatous disease, Gene therapy, Hematopoietic stem cells, Primary immunodeficiencies, RAGs defect, SCID-X1, Wiskott–Aldrich syndrome, XLP1 disease",
author = "Cristina Cifaldi and Francesca Ferrua and Alessandro Aiuti and Caterina Cancrini",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s12210-018-0742-3",
language = "English",
volume = "29",
pages = "755--764",
journal = "ATTI Della Accademia Nazionale Dei Lincei Rendiconti Lincei Scienze Fisiche E Naturali",
issn = "2037-4631",
publisher = "Accademia Nazionale dei Lincei",
number = "4",

}

TY - JOUR

T1 - Hematopoietic stem cell gene therapy for the cure of blood diseases

T2 - primary immunodeficiencies

AU - Cifaldi, Cristina

AU - Ferrua, Francesca

AU - Aiuti, Alessandro

AU - Cancrini, Caterina

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This report provides an overview of gene therapy use of stem cell for the treatment of primary immunodeficiencies (PIDs). Human stem cells are non-specialized cells, able to differentiate, starting from the embryo and for the whole duration of the life of each individual, into different cell types, through two types of cell division: symmetrical creating two stem cells and asymmetric differentiating to any cell lineage. These cells represented the ideal target for gene correction to guarantee production of engineered multi-lineage progeny. Their use in gene therapy led to the development of an effective treatment for PIDs, such as ADA deficiency, SCID-X1, WAS, CGD, and providing potential long-term clinical benefit for affected patients.

AB - This report provides an overview of gene therapy use of stem cell for the treatment of primary immunodeficiencies (PIDs). Human stem cells are non-specialized cells, able to differentiate, starting from the embryo and for the whole duration of the life of each individual, into different cell types, through two types of cell division: symmetrical creating two stem cells and asymmetric differentiating to any cell lineage. These cells represented the ideal target for gene correction to guarantee production of engineered multi-lineage progeny. Their use in gene therapy led to the development of an effective treatment for PIDs, such as ADA deficiency, SCID-X1, WAS, CGD, and providing potential long-term clinical benefit for affected patients.

KW - Adenosine deaminase deficiency

KW - Chronic granulomatous disease

KW - Gene therapy

KW - Hematopoietic stem cells

KW - Primary immunodeficiencies

KW - RAGs defect

KW - SCID-X1

KW - Wiskott–Aldrich syndrome

KW - XLP1 disease

UR - http://www.scopus.com/inward/record.url?scp=85055990023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055990023&partnerID=8YFLogxK

U2 - 10.1007/s12210-018-0742-3

DO - 10.1007/s12210-018-0742-3

M3 - Review article

AN - SCOPUS:85055990023

VL - 29

SP - 755

EP - 764

JO - ATTI Della Accademia Nazionale Dei Lincei Rendiconti Lincei Scienze Fisiche E Naturali

JF - ATTI Della Accademia Nazionale Dei Lincei Rendiconti Lincei Scienze Fisiche E Naturali

SN - 2037-4631

IS - 4

ER -